We are live on ! Find out more
XERS icon

Xeris Biopharma Holdings
XERS

49 hedge funds and large institutions have $161M invested in Xeris Biopharma Holdings in 2019 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,050% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 2

350% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 4

40% more funds holding

Funds holding: 35 → 49 (+14)

7.7% more ownership

Funds ownership: 51.72% → 59.43% (+7.7%)

12% less capital invested

Capital invested by funds: $184M → $161M (-$22.8M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
49
Holders Change
+14
Holders Change %
+40%
% of All Funds
1.06%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
18
Increased
23
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$14.7M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$10.4M
3
ACH
ArrowMark Colorado Holdings
Colorado
+$9.57M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.74M
5
RG
Redmile Group
California
+$7.53M

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$3.45M
2
DM
Deerfield Management
New York
-$1.84M
3
GIM
Granahan Investment Management
Massachusetts
-$1.4M
4
TRCT
Tower Research Capital (TRC)
New York
-$17K
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
TA
26
Teachers Advisors
New York
$283K +$361K +28,196 New
CSS
27
Cubist Systematic Strategies
Connecticut
$258K +$329K +25,693 New
Marshall Wace
28
Marshall Wace
United Kingdom
$245K +$313K +24,451 New
RhumbLine Advisers
29
RhumbLine Advisers
Massachusetts
$232K +$296K +23,061 New
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
$219K +$184K +14,340 +192%
Bank of America
31
Bank of America
North Carolina
$184K +$169K +13,209 +261%
IWM
32
IHT Wealth Management
Illinois
$170K +$217K +16,920 New
M&T Bank
33
M&T Bank
New York
$148K +$189K +14,741 New
AIG
34
American International Group
New York
$131K +$111K +8,655 +197%
Wells Fargo
35
Wells Fargo
California
$123K +$115K +8,994 +273%
ProShare Advisors
36
ProShare Advisors
Maryland
$114K +$145K +11,321 New
JP Morgan Chase
37
JP Morgan Chase
New York
$95K +$99.1K +7,734 +453%
UBS Group
38
UBS Group
Switzerland
$94K – – –
MWNA
39
Marshall Wace North America
New York
$71K +$90.8K +7,087 New
Barclays
40
Barclays
United Kingdom
$61K +$67.2K +5,244 +623%
Citigroup
41
Citigroup
New York
$59K +$56.3K +4,395 +300%
BNP Paribas Financial Markets
42
BNP Paribas Financial Markets
France
$43K +$54.9K +4,287 New
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$39K – – –
Victory Capital Management
44
Victory Capital Management
Texas
$35K – – –
Legal & General Group
45
Legal & General Group
United Kingdom
$35K +$31.8K +2,482 +247%
AIP
46
Ameritas Investment Partners
Nebraska
$17K +$14.6K +1,143 +210%
MAM
47
Meeder Asset Management
Ohio
$4K +$4.88K +381 New
SO
48
STRS Ohio
Ohio
$3K – – –
Daiwa Securities Group
49
Daiwa Securities Group
Japan
$2K -$1.67K -130 -43%
SM
50
Sabby Management
Florida
– -$3.45M -202,916 Closed
1
2
3

XERS Hedge Fund Activity: Q1 2019 in Review

49 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q1 2019, worth a combined $161M — down 12% from $184M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new XERS positions and 4 closed out — a net gain of 14 holders — while 23 added to existing stakes and 2 trimmed.

The largest buyer was BlackRock, adding an estimated $14.7M. The largest seller was Sabby Management, exiting entirely with an estimated $3.45M sold.

  • 49 institutional investors held Xeris Biopharma Holdings (XERS) as of Q1 2019, up from 35 in Q4 2018.
  • Funds reported $161M of Xeris Biopharma Holdings stock for Q1 2019, down 12% quarter-over-quarter.
  • 18 funds opened new Xeris Biopharma Holdings positions in Q1 2019 and 4 closed out, a net change of +14 holders.
  • The largest Xeris Biopharma Holdings buyer in Q1 2019 was BlackRock, an estimated $14.7M added.
  • The largest Xeris Biopharma Holdings seller in Q1 2019 was Sabby Management, an estimated $3.45M sold.

Based on aggregated 13F filings for Q1 2019.